Mirum Pharmaceuticals, Inc. SEC Filings

Mirum Pharmaceuticals reported reported transactions of Common Stock under Form 144 by Christopher Peetz. The filing lists three dispositions: 7,098 shares on 01/22/2026, 6,831 shares on 01/26/2026, and 9,108 shares on 02/02/2026. The shares are described as Restricted Stock Units vesting under registered plan, issued as compensation for services.

Saira Ramasastry reported a proposed sale of Common Stock. The notice covers 2,000 shares to be sold on 03/16/2026 pursuant to a stock option exercise for cash, listed as "ISSUER" in the filing.

The filing also lists recent dispositions by the same holder: 2,000 shares on 02/13/2026 for $204,180.00, 2,000 shares on 01/15/2026 for $181,980.00, 5,000 shares on 12/22/2025 for $400,000.00, and 2,000 shares on 12/18/2025 for $139,460.00.

Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share. These options were fully vested. Following the transaction, he directly owns 26,567 shares of common stock and holds 54,088 stock options.

No shares were sold and no tax-withholding dispositions were reported, making this a straightforward exercise-and-hold transaction that increases his direct equity stake in the company.

Mirum Pharmaceuticals files a shelf registration to permit resale of up to 8,960,998 shares of its common stock. The prospectus covers resale by selling stockholders of 8,960,998 shares, which include shares issued in connection with the January 23, 2026 acquisition of Bluejay, shares held back as indemnity, private placement shares and shares issuable upon exercise of pre-funded warrants.

The company states it will not receive proceeds from these resales and agreed to bear registration expenses; selling stockholders will pay distribution-related fees and commissions. The offering is for resale by holders and is subject to lock-ups and exercise limitations described in the prospectus.

Mirum Pharmaceuticals, Inc. files its annual report describing a focused rare-disease biopharma platform built around bile-acid and CNS therapies. The company highlights three approved medicines—Livmarli for Alagille syndrome and PFIC, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid and peroxisomal disorders—commercialized mainly in the U.S., Canada and parts of Europe.

Mirum details a broad late-stage pipeline, including volixibat for PSC and PBC with multiple Phase 2b readouts expected in 2026, brelovitug for chronic hepatitis D in the global Phase 3 AZURE program, and MRM-3379 for fragile X syndrome in Phase 2 with data expected in 2027. The report also outlines recent business development, including the Travere bile-acid portfolio acquisition and the Bluejay Therapeutics acquisition, extensive license and royalty structures with Shire/Takeda, Pfizer, Sanofi, Novartis and Enthorin, and a large global patent estate with protection for key programs into the 2030s and 2040s.

Mirum Pharmaceuticals reported strong 2025 growth while remaining loss-making. Net product sales rose to $521.3 million from $336.4 million, driven by LIVMARLI at $360.0 million and bile acid medicines at $161.3 million. For 2026, the company guides to global net product sales of $630 million to $650 million.

Total operating expenses increased to $543.4 million from $424.5 million, including $95.0 million of non-cash items, leading to a narrowed full-year net loss of $23.4 million versus $87.9 million in 2024. Unrestricted cash, cash equivalents and investments were $391.4 million as of December 31, 2025, up from $292.8 million, supported by two private placements totaling $268.5 million.

The update highlights multiple late-stage catalysts in 2026, including volixibat VISTAS topline data in PSC in Q2 2026, LIVMARLI EXPAND topline data in Q4 2026, volixibat VANTAGE enrollment completion in H2 2026, and brelovitug AZURE topline HDV data in H2 2026, alongside progress with CTEXLI and MRM-3379.

Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale. On February 13, 2026, she exercised stock options covering 2,000 shares of common stock at an exercise price of $23.51 per share, converting a derivative position into shares.

On the same day, she then sold 2,000 shares of common stock in an open-market transaction at a price of $102.09 per share, leaving 0 common shares owned directly after the sale and 6,000 stock options held directly. The filing states the sale occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, and notes that the stock option involved is fully vested.

Janus Henderson Group plc, through its investment adviser subsidiaries, reports beneficial ownership of 6,065,308 shares of Mirum Pharmaceuticals, Inc. common stock, representing 11.8% of the class as of 12/31/2025.

The shares are held in various managed portfolios, where Janus Henderson’s asset managers exercise shared voting and dispositive power but do not have rights to receive dividends or sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Mirum Pharmaceuticals.

Mirum Pharmaceuticals (MIRM) shareholder Saira Ramasastry has filed a Form 144 indicating an intent to sell 2,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $204,180.00 and an approximate sale date of 02/13/2026 on the NASDAQ.

The 2,000 shares were acquired on 02/13/2026 via a stock option exercise from the issuer, paid in cash. The notice also lists prior sales over the past three months, including 2,000 common shares sold on 01/15/2026 for $181,980.00, 5,000 shares on 12/22/2025 for $400,000.00, and 2,000 shares on 12/18/2025 for $139,460.00. Shares of common stock outstanding were 51,393,574 as of the filing details, a baseline figure separate from the planned sale amount.